Demant A/S (OTCMKTS:WILYY) Stock Rating Lowered by UBS Group

Demant A/S (OTCMKTS:WILYY) was downgraded by research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

WILYY has been the topic of a number of other research reports. Sanford C. Bernstein lowered Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. Morgan Stanley raised Demant A/S from an “equal weight” rating to an “overweight” rating in a report on Tuesday, June 23rd. Finally, Zacks Research upgraded shares of Demant A/S to a “hold” rating in a research report on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Demant A/S Price Performance

Shares of WILYY stock opened at $20.66 on Wednesday. The stock has a 50 day simple moving average of $19.59 and a 200-day simple moving average of $16.95. Demant A/S has a 12-month low of $13.45 and a 12-month high of $20.98. The company has a debt-to-equity ratio of 1.65, a current ratio of 1.36 and a quick ratio of 1.00.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.